PMID- 1607734
OWN - NLM
STAT- MEDLINE
DCOM- 19920722
LR  - 20191021
IS  - 0265-6736 (Print)
IS  - 0265-6736 (Linking)
VI  - 8
IP  - 3
DP  - 1992 May-Jun
TI  - Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) 
      combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
PG  - 297-304
AB  - Seventeen patients with chemotherapy-resistant metastatic sarcoma were treated 
      with whole body hyperthermia (WBH) combined simultaneously with 
      1-3-Bis(2-chloroethyl)-1-nitrosourea (BCNU). All of the patients had chemotherapy 
      resistant metastases to major organ sites. Patients were heated to 41.8-42.0 
      degrees C for 2 h using an insulated blanket heating technique. Two patients 
      (12%) experienced partial responses (PR). In addition, four objective tumour 
      responses (OR) lasting more than 4 months were documented. One patient with 
      previously rapidly growing chondrosarcoma pulmonary metastases experienced stable 
      disease (SD) for 38 months from the onset of treatment. Median survival of seven 
      patients with responding tumours (PR, OR and SD) compared with 10 patients with 
      progressive disease was 15 versus 2 months, respectively. Cumulative 
      thrombocytopenia was a therapy-limiting toxicity of the combined treatment, and 
      occurred in six of seven patients. Acute toxicities attributable to WBH alone 
      included transient thrombocytopenia in all patients, non-cardiogenic pulmonary 
      oedema in two patients, and mild hypotension in five patients. Acute 
      granulocytosis was observed in all patients. No treatment related deaths 
      occurred. These data suggest that WBH combined with chemotherapy is associated 
      with disease response in patients with chemotherapy-resistant, widely 
      disseminated sarcoma metastases.
FAU - Bull, J M
AU  - Bull JM
AD  - Houston Department of Internal Medicine, University of Texas Medical School 
      77030.
FAU - Cronau, L H
AU  - Cronau LH
FAU - Newman, B M
AU  - Newman BM
FAU - Jabboury, K
AU  - Jabboury K
FAU - Allen, S J
AU  - Allen SJ
FAU - Ohno, S
AU  - Ohno S
FAU - Smith, T
AU  - Smith T
FAU - Tonnesen, A S
AU  - Tonnesen AS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Carmustine/*therapeutic use
MH  - Combined Modality Therapy
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - *Hyperthermia, Induced/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Edema/etiology
MH  - Sarcoma/drug therapy/secondary/*therapy
MH  - Thrombocytopenia/etiology
EDAT- 1992/05/01 00:00
MHDA- 1992/05/01 00:01
CRDT- 1992/05/01 00:00
PHST- 1992/05/01 00:00 [pubmed]
PHST- 1992/05/01 00:01 [medline]
PHST- 1992/05/01 00:00 [entrez]
AID - 10.3109/02656739209021784 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 1992 May-Jun;8(3):297-304. doi: 10.3109/02656739209021784.